TSXV:BTI.H - Post by User
Comment by
BearDownAZon Aug 04, 2015 12:46pm
112 Views
Post# 23987331
RE:RE:Whatever happened to the Sandhoff LSD study?
RE:RE:Whatever happened to the Sandhoff LSD study?"What difference does it make?"
The only real knock on the Scarpa announcement for the MPS II Hutner Syndrome study was Scarpa's statement "I am very encouraged that after some adjustments regarding dosing, we might be able to move this program into the clinic."
If Bioasis has an analagous LSD model (Sandhoff disease) requiring HEXB replacement into a HEXB-knockout animal AND these studies are being done locally in Vancouver at UBC, then essentially they 1) Have a second animal model to validate metabolic enzyme replacement; and 2) may have already completed, in the process of completing or very easily do in the near future the optimal dosing studies Scarpa referred to for the MPS II study.
And lastly, since when is questioning the status of a pre-clinical study 1) of great interest 2) of relevance to other recent LSD announcements and 3) that was announced as starting around October 2014 become equated with trolling/day trading?